Anzeige
Meldung des Tages: 0,01 % von 1 BILLIONEN USD = 100 MILLIONEN USD — Und UberDoc ist gerade erst an die Börse gegangen

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB Branche:  Pharmazeutika Land:  USA
172,91 $
-4,20 $
-2,37%
147,47 € 10.04.26
Depot/Watchlist
Marktkapitalisierung *
22,04 Mrd. €
Streubesitz
3,72%
KGV
11,76
Nachhaltigkeits-Score
49 %
Index-Zuordnung
Nasdaq 100
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,42: JU32NM
Werbung

Biogen News

05.12.25 - GlobeNewswire
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-​seizure medicines (ASMs) demonstrate durable seizure reductions, ...
03.12.25 - PR Newswire
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-​irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on ...
02.12.25 - PR Newswire
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-​irmb) on Neurotoxic Aβ ...
02.12.25 - dpa-AFX
Institut: Alzheimer-Medikament Lecanemab von Biogen hat keinen Zusatznutzen
Schlechte Nachrichten für den US-​Hersteller Biogen und seinen japanischen Partner Eisai: Ein umfassender Report sieht keinen Beweis für einen Zusatznutzen ihres Alzheimer-...
25.11.25 - PR Newswire
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-​irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...
24.11.25 - GlobeNewswire
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Oral macrocyclic peptides have the potential to offer biologic-​like efficacy and safety in a convenient oral format Collaboration further advances Biogen’s immunology strategy by ...
17.11.25 - GlobeNewswire
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
– Despite treatment with standard-​of-care anti-​seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a ...
17.11.25 - GlobeNewswire
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-​naive participants and those transitioning from ...
14.11.25 - GlobeNewswire
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-​stage biotechnology ...
03.11.25 - GlobeNewswire
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Oral presentation to share first-​of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing ...
30.10.25 wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus!
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
25.10.25 wallstreetONLINE Redaktion
Gewinner der Börsengeschichte: US-Biotech-Perle: +37.497 % in 30 Jahren: Aus 1.000 wurden 375.000 USD!
Nicht Nvidia, Amazon, Netflix oder Apple. Ein börsennotiertes Biotech-​Unternehmen aus Massachusetts hat Aktionären innerhalb von 30 Jahren +37.497 Prozent Rendite gebracht. ...
24.10.25 - GlobeNewswire
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
The oral C5aR1 antagonist is designed to modulate neutrophil-​driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and ...
22.10.25 - GlobeNewswire
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, ...
14.10.25 - GlobeNewswire
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters ...
13.10.25 - PR Newswire
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
LEQEMBI® IQLIK™(lecanemab-​irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" PR Newswire
09.10.25 - GlobeNewswire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results ...
06.10.25 - GlobeNewswire
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with ...
06.10.25 - PR Newswire
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-​irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease PR Newswire
03.10.25 - dpa-AFX
Erste Patienten bekommen Alzheimer-Mittel Lecanemab
Seit gut einem Monat ist das Alzheimer-​Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit ...

Newssuche

Videos

newspaper
07.04.26 -4,86%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »